Navigation Links
Clinic puts patients at heart of multiple sclerosis research
Date:8/31/2010

A research clinic for multiple sclerosis patients is being set up with a 10 million donation from the author J K Rowling.

The Anne Rowling Regenerative Neurology Clinic at the University of Edinburgh will place patients at the heart of research to improve outcomes for multiple sclerosis sufferers.

This will focus on patient-based studies to help find treatments that could slow progression of the disease, working towards the eventual aim of stopping and reversing it.

The Anne Rowling Regenerative Neurology Clinic is named after Ms Rowling's mother, who died of multiple sclerosis aged 45.

Work at the clinic will also provide insight into other degenerative neurological conditions, such as Alzheimer's disease, Parkinson's disease, Huntington's disease and Motor Neurone Disease.

As with multiple sclerosis, these disorders are progressive and incurable.

The clinic follows on from the setting up of the Centre for Multiple Sclerosis Research at the University in 2007, which has also received support from the Harry Potter author.

Ms Rowling said: "I cannot think of anything more important, or of more lasting value, than to help the university attract world-class minds in the field of neuroregeneration, to build on its long and illustrious history of medical research and, ultimately, to seek a cure for a very Scottish disease." (A full statement from J K Rowling is below.)

The Anne Rowling Regenerative Neurology Clinic will be based in a purpose-built facility within the University's Chancellor's Building, next to the city's Royal Infirmary and within Edinburgh BioQuarter at Little France. This development will build on Edinburgh's strong track records in patient-focused clinical research on neurological disorders and in imaging of the brain and nervous system.

It is the single largest donation that the author has given to a charitable cause. This is also the largest single donation that the University has received.

Clinical academics will work closely with a critical mass of researchers studying neurodegenerative disorders already based at the University.

This will include expertise from the Centre for Multiple Sclerosis Research, the MRC Centre for Regenerative Medicine, the Centre for Neuroregeneration, Euan MacDonald Centre for Motor Neuron Disease Research and Division of Clinical Sciences.

There will also be a major emphasis on training the next generation of researchers.

Professor Sir Timothy O'Shea, Principal of the University of Edinburgh, said: "This exceptionally generous donation will provide great help in the worldwide effort to improve treatments for multiple sclerosis. Work at the clinic will build on the already existing important research strengths in neurodegenerative disorders at the University, which benefit very considerably from our close partnership with NHS Lothian."

Multiple sclerosis affects around 100,000 people in the UK. Scotland has one of the highest rates of multiple sclerosis in the world, with some 10,500 people with the condition.

While there is some evidence to suggest that multiple sclerosis is caused by a combination of genetics and environmental factors the exact cause of the disease is not fully understood.

Professor Charles ffrench-Constant, co- director of the University of Edinburgh's Centre for Multiple Sclerosis Research and Director-elect the MRC Centre of Regenerative Medicine, said: "We can only find improved treatments if we can truly understand diseases and the biological processes behind them. The Anne Rowling Regenerative Neurology Clinic will enable us to carry out studies that can inform laboratory research and, in turn, this knowledge can be translated back into treatments for patients."

Multiple sclerosis causes myelin a protective layer surrounding nerve cells in the brain to break down. This then leads to the nerve cells, which send messages from the brain to other parts of the body, becoming damaged.

This can cause symptoms such as numbness, visual loss, fatigue, dizziness and weakness that lead to accumulating disability.

As with other neurological disorders, once the nerve cells are damaged they are not replaced causing the condition to progressively worsen.

Siddharthan Chandran, Professor of Neurology and co-director of the Centre for Multiple Sclerosis Research, said: "Multiple sclerosis has many features in common with other neurodegenerative disorders. As a result any discoveries from the Anne Rowling Regenerative Neurology Clinic will help us advance our understanding and treatment of all these related neurological diseases. Finding ways to slow progression of these conditions will make an enormous difference to patients' lives."

The donation is part of the Edinburgh Campaign, which aims to raise 350 million for initiatives across the University. This includes creating new hubs of learning, conserving iconic University buildings, furthering research and increasing the number of scholarships and bursaries available for students.


'/>"/>

Contact: Tara Womersley
tara.womersley@ed.ac.uk
01-316-509-836
University of Edinburgh
Source:Eurekalert

Related medicine news :

1. The West Clinic Joins Cancer Clinics of Excellence (CCE)
2. Stethoscope App gives iPhone New Clinical Skills
3. Mayo Clinic responsible for $22 billion in economic impact, including $9.6 billion in Minnesota
4. Sunquest Introduces Integrated Clinical Environment Physician Portal Solution in US
5. Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials
6. Clinical trial underway: Miniature ultrasound device could revolutionize pain relief
7. Sunquest Completes System-Wide Implementation at Cleveland Clinic Hospital Laboratories
8. Michael J. Fox Foundation Awards $1.1 Million For Clinical Trial of Transdermal Nicotine as Disease-Modifying Treatment For Parkinsons
9. NOVAVAX Presents Positive Clinical Results at The World Health Organization Conference, Geneva, Switzerland
10. UCLA Health System Presents: How to Successfully Implement a Clinical Portal
11. International Merchant Advisors CEO Mel Roseman to Discuss New Medical Marijuana Clinics Live on CBS Radio Networks Big Biz Show February 22, 2010 at 1:40 pm PST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... National recruitment firm ... life sciences executive with extensive sequencing and genomics experience, as Vice President of North ... Ms. Hill will be responsible for leading the sales team in the commercialization of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology: